2-Ethyl-4,5-tetramethylen-thiophen | 40808-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-Ethyl-4,5-tetramethylen-thiophen
• 英文别名: 2-ethyl-4,5,6,7-tetrahydro-benzo[b]thiophene；2-Aethyl-4,5,6,7-tetrahydro-benzo[b]thiophen；2-Ethyl-4,5,6,7-tetrahydro-1-benzothiophene
• CAS: 40808-51-3
• 化学式: C₁₀H₁₄S
• 分子量: 166.287
• InChiKey: KHLDOFLJCAKDOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Ethyl-4,5-tetramethylen-thiophen 生成 1-(2-ethyl-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-ethanone-(2,4-dinitro-phenylhydrazone)
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1953, p. 62,68, 713, 717

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4,5,6,7-tetrahydro-benzo[b]thiophen-2-yl)-ethanone 在 氢氧化钾 、 一水合肼 、 二乙二醇 作用下， 生成 2-Ethyl-4,5-tetramethylen-thiophen
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1953, p. 62,68, 713, 717

  摘要：

  DOI：

文献信息

• CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：BLOMGREN Peter A.

  公开号：US20090082330A1

  公开（公告）日：2009-03-26

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  公式I的化合物能够抑制Btk，本文中对此进行了描述。描述了包含至少一个公式I化合物的药物组合物，以及至少一个从载体、佐剂和辅料中选择的药用辅料。描述了治疗患有对Btk活性抑制和/或B细胞活性有反应的某些疾病患者的方法。还描述了用于确定样本中存在Btk的方法。
• FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
  申请人：Shigeta Yukihiro

  公开号：US20120209005A1

  公开（公告）日：2012-08-16

  Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 is an aryl group fused to a saturated ring or the like, A, B, L 1 , R 2 , L 2 , L 3 , Y, L 4 , R 3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了对激活血小板生成素受体有效的疾病的预防、治疗或改善有用的融合杂环化合物。代表式(I)的化合物（其中R1是与饱和环或类似物融合的芳基，A、B、L1、R2、L2、L3、Y、L4、R3和X在描述中有定义），该化合物的互变异构体、前药或药用可接受的盐或其溶剂化物。
• Certain Substituted Amides, Method of Making, and Method of Use Thereof
  申请人：Blomgren Peter A.

  公开号：US20110059944A1

  公开（公告）日：2011-03-10

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物I的配方。本文还描述了包括至少一种化合物I的制药组合物，以及至少一种从载体、佐剂和赋形剂中选择的药用可接受载体。本文还描述了治疗对抑制Btk活性和/或B细胞活性敏感的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
• PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Barbosa JR. Antonio J.M.

  公开号：US20110301145A1

  公开（公告）日：2011-12-08

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了化学式I的化合物，其能够抑制Btk。本文还描述了包含至少一种化学式I化合物的制药组合物，以及至少选择自载体、佐剂和赋形剂中的一种药学可接受载体的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制有响应的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
• BICYCLIC COMPOUND
  申请人：TOA EIYO LTD.

  公开号：US20150119418A1

  公开（公告）日：2015-04-30

  Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C 1 -C 3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X 1 and X 2 each independently represent CH or N; W 1 and W 2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C 1 -C 8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.

  提供一种含有由通式（1）表示的化合物、其药学上可接受的盐或溶剂的制药剂：其中A代表C1-C3线性烷基，其中一个亚甲基团可以选择性地被O或S取代；n代表3到5的整数；X1和X2分别独立地表示CH或N；W1和W2分别独立地表示羧基或四唑基；V表示C1-C8线性或支链烷基，其中一个亚甲基团可以选择性地被O或S取代；R代表取代苯基。